Product Description
The research-grade biosimilar is a recombinant humanized IgG1 monoclonal antibody that targets ganglioside GD2. GD2 is a disialoganglioside that is expressed in neuroblastomas, melanomas, bone and soft tissue sarcomas, brain tumors, and small cell lung cancer. Although its function is not clearly understood, it may be playing an essential role in attaching tumor cells to extracellular matrix proteins. Due to its tumor-specific expression, GD2 serves as a suitable target for tumor-specific antibody therapy. The antibody binds to GD2 and causes cell death via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). The original monoclonal antibody is FDA approved to treat adult and pediatric patients suffering from relapsed/refractory neuroblastoma.
Biovision | A2273 | Anti-GD2 (Naxitamab), Humanized Antibody DataSheet
Antibody Target: GD2 Ganglioside
Target Alternative Name: GD2 Ganglioside, GD2, CAS 65988-71-8
Tag Line: The biosimilar is a humanized monoclonal antibody that targets ganglioside GD2
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human GD2
Accession #: DB15965
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration:
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE